Detalhe da pesquisa
1.
Iraqi regulatory authority current system and experience with biosimilars.
Regul Toxicol Pharmacol
; 117: 104768, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32861742
2.
Biosimilars: where we were and where we are.
J Biopharm Stat
; 24(6): 1154-64, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25036475
3.
Pharmacokinetic Profiles of a Proposed Biosimilar Ustekinumab (BFI-751): Results From a Randomized Phase 1 Trial.
Clin Pharmacol Drug Dev
; 12(10): 1001-1012, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37483071
4.
Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
Ann Hematol
; 89(9): 927-33, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20428872
5.
Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
Ann Hematol
; 89(10): 971-8, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20567823
6.
A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer.
Onkologie
; 33(10): 504-11, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20926897